Ocular Therapeutix (OCUL) Total Liabilities (2013 - 2026)

Ocular Therapeutix's Total Liabilities history runs 14 years deep, the most recent figure standing at $151.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 7.83% year-over-year to $151.0 million in Q1 2026; TTM through Mar 2026 was $151.0 million, a 7.83% increase from a year earlier, with the FY2025 full-year figure at $153.7 million, up 7.82% from the prior year.
• Total Liabilities retreated to $151.0 million in Q1 2026 per OCUL's latest filing, from $153.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $160.9 million in Q4 2023 and bottomed at $107.3 million in Q2 2022.
• The 5-year median for Total Liabilities is $139.4 million (2024), against an average of $134.7 million.
• Across the five-year window, Total Liabilities tumbled 32.45% in 2022 and surged 41.28% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $113.9 million in 2022, then jumped by 41.28% to $160.9 million in 2023, then fell by 11.4% to $142.6 million in 2024, then climbed by 7.82% to $153.7 million in 2025, then slipped by 1.82% to $151.0 million in 2026.
• Per Business Quant, the three latest OCUL Total Liabilities figures stand at $151.0 million (Q1 2026), $153.7 million (Q4 2025), and $152.7 million (Q3 2025).